EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Robert W. Baird from $46.00 to $38.00. They now have an "outperform" rating on the stock.
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments [Yahoo! Finance]
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Chardan Capital from $39.00 to $28.00. They now have a "buy" rating on the stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Mizuho from $39.00 to $30.00. They now have a "buy" rating on the stock.